{"filing":{"accession_number":"0001730463-26-000112","cik":"0001730463","ticker":"AUTL","company_name":"Autolus Therapeutics plc","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"autl-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000112/autl-20260803.htm"},"events":[{"id":23457,"run_id":21208,"accession_number":"0001730463-26-000112","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Autolus disclosed preliminary Q2 2026 net product revenue of approximately $45 million for AUCATZYL and raised full-year 2026 revenue guidance to $140–$150 million from $120–$135 million, with gross margin improvement to approximately 35% year-to-date. Full Q2 2026 financial results are expected to be reported on August 11, 2026.","company_name":"Autolus Therapeutics plc","ticker":"AUTL","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23686,"accession_number":"0001730463-26-000112","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses preliminary Q2 2026 net product revenue of approximately $45 million for AUCATZYL and updates full-year 2026 revenue guidance upward to $140–$150 million from $120–$135 million, along with gross margin improvement to approximately 35% year-to-date. While the press release also announces a credit facility, the Item 2.02 disclosure centers on financial results and revenue guidance updates, which are the hallmarks of an earnings release. The company notes it will report full Q2 2026 financial results on August 11, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:33:36.687789+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":23458,"run_id":21208,"accession_number":"0001730463-26-000112","anchor_item_number":"8.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Autolus entered into a strategic credit facility with Perceptive Advisors for up to $250 million in senior notes, with $75 million funded at closing on July 30, 2026, and an additional $25 million available at the Company's option, strengthening the Company's capital base and extending cash runway into Q2 2028.","company_name":"Autolus Therapeutics plc","ticker":"AUTL","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23687,"accession_number":"0001730463-26-000112","item_number":"8.01","item_title":"Other Events.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into a strategic credit facility with Perceptive Advisors for up to $250 million in senior notes, with $75 million funded at closing on July 30, 2026, and an additional $25 million available at the Company's option. While the disclosure also includes a revenue guidance increase and preliminary Q2 results, the principal Item 8.01 event centers on the creation of this new direct financial obligation. The debt issuance is material as it strengthens the Company's capital base and extends cash runway into Q2 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:33:36.687789+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23686,"accession_number":"0001730463-26-000112","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses preliminary Q2 2026 net product revenue of approximately $45 million for AUCATZYL and updates full-year 2026 revenue guidance upward to $140–$150 million from $120–$135 million, along with gross margin improvement to approximately 35% year-to-date. While the press release also announces a credit facility, the Item 2.02 disclosure centers on financial results and revenue guidance updates, which are the hallmarks of an earnings release. The company notes it will report full Q2 2026 financial results on August 11, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:33:36.687789+00:00","company_name":"Autolus Therapeutics plc","ticker":"AUTL","filing_date":"2026-08-03"},{"id":23687,"accession_number":"0001730463-26-000112","item_number":"8.01","item_title":"Other Events.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into a strategic credit facility with Perceptive Advisors for up to $250 million in senior notes, with $75 million funded at closing on July 30, 2026, and an additional $25 million available at the Company's option. While the disclosure also includes a revenue guidance increase and preliminary Q2 results, the principal Item 8.01 event centers on the creation of this new direct financial obligation. The debt issuance is material as it strengthens the Company's capital base and extends cash runway into Q2 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:33:36.687789+00:00","company_name":"Autolus Therapeutics plc","ticker":"AUTL","filing_date":"2026-08-03"}]}